MECHANISM OF ACTION
RYBREVANT® + LAZCLUZE™ achieve multitargeted inhibition of EGFR and MET, with the addition of CNS penetration1-3
- RYBREVANT® is the first and only approved EGFR-MET bispecific antibody with immune cell–directing activity1,4,5
- LAZCLUZE™ is a third-generation TKI that is a suitable combination partner for RYBREVANT® because of high selectivity for mutant EGFR, low selectivity for wild-type EGFR, and because it is CNS–penetrant2,3
RYBREVANT® + LAZCLUZE™
*Trogocytosis is a process in which one cell, in this case a macrophage, physically extracts and ingests cellular material of another cell.6
†ADCC involves the release of cytotoxic granules that cause tumor cell death.4,7
RYBREVANT® + LAZCLUZE™ is a chemotherapy-sparing combination that provides complementary extra- and intracellular antitumor activity and CNS penetration1-4
ADCC, antibody-dependent cellular toxicity; CNS, central nervous system; EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition; TKI, tyrosine kinase inhibitor.
RYBREVANT® + CHEMOTHERAPY
*Trogocytosis is a process in which one cell, in this case a macrophage, physically extracts and ingests cellular material of another cell.6
†ADCC involves the release of cytotoxic granules that cause tumor cell death.4,7
References:
1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
2. LAZCLUZE™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
3. Yun J, Hong MH, Kim SY, et al. YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non–small cell lung cancer. Clin Cancer Res. 2019;25(8):2575-2587.
4. Cho BC, Simi A, Sabari J, et al. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89-97.
5. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. Press release. Johnson & Johnson. August 20, 2024. Accessed August 20, 2024.
https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-us-as-a-first-line-chemotherapy-free-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer-302226047.html
6. Bettadapur A, Miller HW, Ralston KS. Biting off what can be chewed: trogocytosis in health, infection, and disease. Infect Immun. 2020;88(7):e00930-19.
7. Grugan KD, Dorn K, Jarantow SW, et al. Fc-mediated activity of EGFR x c-MET bispecific antibody JNJ-61186372 enhanced killing in lung cancer cells. MAbs. 2017;9(1):114-126.
8. Schaer DA, Geeganage S, Amaladas N, et al. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy. Clin Cancer Res. 2019;25(23):7175-7188.
9. Schoch S, Gajewski S, Rothfuß J, et al. Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics. Int J Mol Sci. 2020;21(18):6928.